Covalon Technologies : Q2 FY2024 Financial Results

TSX-V: COV

OTCQX: CVALF

[e-mail]

Q2 FY'24 Earnings Presentation

May 29, 2024

Brent Ashton - CEO

Katie Martinovich - Interim CFO

Compassionate solutions designed for patients and made for care providers

1

Forward-Looking Statements and Non-GAAP Financial Information

Certain statements included in this presentation may be considered forward-looking statements. These forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could", or "might" occur or be achieved and other similar expressions. More specifically, this presentation contains forward-looking statements which include, but are not limited to statements regarding: the Company's corporate strategy and strategic objectives; the availability of external financing to fund the Company's ongoing liabilities and commitments; and economic events. These forward-looking statements involve risk and uncertainties, including the impact on the Company given its current liquidity situation, the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results, and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Such forward-looking statements should not be taken as guarantees of future performance of Covalon.

All forward-looking statements are based on Covalon's current beliefs as well as assumptions made by and information currently available to Covalon and relate to, among other things, anticipated financial performance, business prospects, partnership opportunities, strategies, regulatory developments, market acceptance and future commitments. The reader is cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation.

Due to risks and uncertainties, including the risks and uncertainties identified by Covalon in its public securities filings, actual events may differ materially from current expectations. Covalon disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Certain financial measures in this presentation - namely earnings before interest, depreciation and amortization ("EBITDA"), adjusted EBITDA, pro-forma EBITDA, free cash flow and enterprise value - are non-GAAP financial measures. While Covalon and certain of its competitors measure and evaluate the performance of their respective consolidated operations and business segments with reference to these and similar measures, non-GAAP measures do not have any standardized or prescribed meaning under IFRS Accounting Standards or otherwise and therefore are unlikely to be comparable to similar measures presented by other companies. These non-GAAP measures should not be considered in isolation or as a substitute for financial measures prepared in accordance with IFRS Accounting Standards. All non-GAAP measures are included because management monitors and uses the information on a regular basis to analyze the performance of the business and therefore may be considered useful information.

For further information about the risks and uncertainties relating to forward-looking statements included in this Memorandum, the recipient should consult the "Risks and Uncertainties" section of Covalon's annual MD&A dated January 26th, 2024, as well as those contained in Covalon's interim MD&As and other public record filings on SEDAR+.

All figures are in Canadian dollars, unless otherwise noted, and Covalon's fiscal year end is September 30th.

2

Q2 Results Demonstrate Solid Focus and Execution

Positive EBITDA of $1.7 million and Adjusted EBITDA of $2.5 million

• Achieved through substantial restructuring, prioritized efforts, and focused execution over the past 8 months
• First positive EBITDA quarter in over 2 years

Strong overall YoY revenue growth of 16%

• Led by focus on US Product segment - revenue up 54% YoY

Identification of, and solid initial progress on, key foundational activities to position company for future success

"We delivered a very strong second quarter - a testament to the value that our products bring to our customers and their patients as well as the hard work of our One Covalon team.

The combination of high revenue growth, expanded operating margins and smarter, reduced operating expenses propelled us to a return to profitability as a company. We are building momentum and are very optimistic about the remainder of fiscal 2024 and beyond".

Brent Ashton

Covalon CEO

3

Covalon Has Created 3 Focused Business Platforms

Covalon is where compassion meets innovative technology. Our commitment to

transforming healthcare goes beyond technology-it's about infusing care with empathy,

understanding, and a relentless pursuit of excellence

Advanced Wound Care	Vascular Access & Post-	Medical Device Coatings
	Operative Dressings

*Covalon's solutions can play a role supporting industry guidelines aimed at infection control. Covalon does not make any claims that its products prevent or reduce the incidence of infection or the transmission of disease. For all products, refer to the intended use. Claims may differ depending on region.

** Various Market Research sources including Grand View Research and Market Research Future

Q2 FY'24 Financial Results

Q2 Key Financial Metrics

Q2 Revenues By Geographies

Total Revenue

$8.41 M

16.1% YoY Growth

Gross Profit

63.1%

560 bps YoY improvement

Net Income

$1.46 M

Product Revenue

$8.39 M

37.3% YoY Growth

Operating Expenses

$3.83 M

YoY reduction of 21.8%

Adjusted EBITDA

$2.49 M

Rest of World

21%

USA 79%

$2.16 M YoY improvement

$2.96 M YoY improvement

Q2 FY'24 P&L / EBITDA

	Q2 FY'24	Q2 FY'23	Delta
Revenue	$8.4	$7.2	+ 16.1%
Gross Profit	$5.3 (63.1%)	$4.2 (57.5%)	+ 560 bps
(Gross Margin)
Operating	$3.8 (45.4%)	$4.9 (67.5%)	- 2,210 bps
Expenses
(% to Revenue)
EBITDA	$1.7 (20.3%)	-$0.5 (-6.4%)	+ $2.2
(% to Revenue)
Adjusted	$2.5 (29.6%)	-$0.5 (-6.5%)	+ $3.0
EBITDA
(% to Revenue)
Net Income	$1.5	-$0.7	+ $2.2 M
EPS	$.06	-$0.03	+ $.09
(cents per share)

All $ figures in $CAD millions (except for EPS which is in $USD)

Revenue growth led by US Product Sales (+54% YoY)

Margin improvement from investments in in-house manufacturing and strong product mix

Operating expense improvement driven by lower but more effective sales and marketing investments

6

Q2 FY'24 Balance Sheet and Cash

	Q3	Q4	Q1	Q2
	FY'23	FY'23	FY'24	FY'24
Cash	$9.2	$8.8	$8.3	$7.3
Net Working	$18.6	$16.1	$14.7	$16.9
Capital
Shareholders'	$21.1	$18.8	$17.7	$19.8
Equity
Debt	$----	$----	$----	$----
Current Ratio	5.4	4.1	4.8	6.8

All $ figures in $CAD millions

Stabilizing cash position

Strong improvement in Net Working Capital and Shareholders' Equity

Zero Debt

Commentary

Point 2

7

Building Momentum for an Exciting Future

Solid Financial

Position

• Zero debt and stabilized cash position
• Expanding gross profit margins
• Right-sizedoperating expenses

Valued Product

Offerings

• Our products help to solve challenging clinical problems
• Peer-to-peerrecommendations and marketing investments driving increased awareness and adoption

Strong Future

Growth Potential

• Favorable market trends
• Robust hopper of opportunities
• Energized and focused team - building new culture

Covalon's Value is Recognized by Leading Health Systems

Strong relationships with leading Children's Hospitals

Solid progress made with leading providers in the United States and Internationally

9

Summary

Q2 was a strong outcome - the result of great work from the One Covalon team

We have line of sight to continuing the momentum of the business - for the remainder of FY'24 and beyond

Extensive foundational work initiated

• will unlock significant value realization for Covalon

10